In the final webinar in this series focusing on obesity, hosted by ABCD and GIRFT and supported by Novo Nordisk Ltd, this session brings together experienced Physician, GP and surgical colleagues for expert case discussions to aid colleagues managing people with obesity across healthcare sectors.
Would you be interested in being a research centre for a clinical trial of a culturally-tailored T2D self-management programme for Black African-Caribbean adults?
People with diabetes on haemodialysis represent a complex group that are at high-risk for medical complications including hypoglycaemia. Furthermore, these individuals have historically not received the attention to their glycaemic control that would be required for their long-term health and expected according to guidelines for managing people with diabetes. The glycaemic assessment of individuals on haemodialysis is difficult to interpret owing to inaccuracies in commonly used measures of glycaemia.
Canagliflozin, Empagliflozin and Dapagliflozin audits
Related Resource: ASO Position Statement: Weight stigma and discrimination
Canagliflozin, Empagliflozin and Dapagliflozin audits
TSJ Crabtree, Dev Sennik, Anurita Rohilla, Alex Bickerton, Dennis Barnes, Siva Sivappriyan, Hazel Reid, Karen Adamson, Suzanne Phillips, Alison Evans, Ian Gallen, REJ Ryder on behalf of the ABCD nationwide semaglutide audit contributors
The ABCD DIY APS audit was conceived in 2019 as a way of recording and assessing the real-world clinical outcomes associated with do-it-yourself artificial pancreas systems.
This management guideline has been jointly developed by ABCD and the Renal Association and focuses on monitoring strategies designed to improve safety and assist in the more effective treatment of individuals who have advanced chronic kidney disease requiring dialysis alongside their diabetes.
